# A First-in-Human Study of HP-002 for Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

> **NCT07658352** · PHASE1,PHASE2 · NOT_YET_RECRUITING · sponsor: **Shanghai Helioson Pharmaceutical Co., Ltd.** · enrollment: 114 (estimated)

## Conditions studied

- B-Cell Non-Hodgkin Lymphoma

## Interventions

- **DRUG:** HP-002

## Key facts

- **NCT ID:** NCT07658352
- **Lead sponsor:** Shanghai Helioson Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-06-26
- **Primary completion:** 2029-06-26
- **Final completion:** 2031-06-26
- **Target enrollment:** 114 (ESTIMATED)
- **Last updated:** 2026-06-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07658352

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07658352, "A First-in-Human Study of HP-002 for Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07658352. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*